Journal: bioRxiv

Article Title: Graded heterogeneity of metabotropic signaling underlies a continuum of cell-intrinsic temporal responses

doi: 10.1101/2020.12.27.424473

Figure Lengend Snippet: a. Schematics of cerebellar circuit b. UMAP embedding showing normalized expression of gene involved in mGluR1 signaling cascade. c. Same as in D for AMPA and NMDA receptors. d. Same as in D for genes involved in mGluR2 signaling cascade. e. Example spiking responses in different UBCs to a burst of MF input (20 stimuli at 100Hz). f. Instantaneous firing rate for the same cells.

Article Snippet: Sequential drug wash-ins were performed using a computer-controlled solenoid manifold system (ValveLink 8.2, Automate Scientific, Inc., Berkeley, CA) with a flow rate of 1 to 2mL/min, where indicated, with mGluR1 antagonist (100μM LY357385, Tocris Bio-Techne, Minneapolis, MN), AMPA receptor blocker (5μM NBQX), NMDA receptor blocker (2 μM R-CPP), mGluR2/3 antagonist (1μM LY341495, Tocris Bio-Techne, Minneapolis, MN) and DGK inhibitor II (100 μM R59949, MilliporeSigma, St. Louis, MO)

Techniques: Expressing

Journal: bioRxiv

Article Title: Graded heterogeneity of metabotropic signaling underlies a continuum of cell-intrinsic temporal responses

doi: 10.1101/2020.12.27.424473

Figure Lengend Snippet: a. Examples of instantaneous firing rate from on-cell recordings before (black) and after (gray) the application of AMPA/NMDA receptor antagonist (gray bar) in a fast (left) and a slow (right) UBC. Each trace is an average of 8 trials. b. Summary of evoked spiking (20×100 Hz) and the effect of AMPA/NMDA receptor antagonist (normalized to baseline, mean±sem, n=5). c. Examples of instantaneous firing rate from on-cell recordings before (black) and after (red) the application of an mGluR1 antagonist (red bar) in a fast (left) and a slow (right) UBC. Each trace is an average of 8 trials. d. Summary of evoked spiking (20×100 Hz) and the effect of an mGluR1 antagonist (normalized to baseline, mean±sem, n=5). e. Example of instantaneous firing rate before and after 20 minutes of DGK inhibitor II wash-in. f. Summary of half-decay time of instantaneous firing rate response with DGK inhibitor II (normalized to baseline, mean±sem, n=6) g. Summary of peak amplitude of instantaneous firing rate response with DGK inhibitor II (normalized to baseline, mean±sem, n=6)

Article Snippet: Sequential drug wash-ins were performed using a computer-controlled solenoid manifold system (ValveLink 8.2, Automate Scientific, Inc., Berkeley, CA) with a flow rate of 1 to 2mL/min, where indicated, with mGluR1 antagonist (100μM LY357385, Tocris Bio-Techne, Minneapolis, MN), AMPA receptor blocker (5μM NBQX), NMDA receptor blocker (2 μM R-CPP), mGluR2/3 antagonist (1μM LY341495, Tocris Bio-Techne, Minneapolis, MN) and DGK inhibitor II (100 μM R59949, MilliporeSigma, St. Louis, MO)

Techniques:

Journal: bioRxiv

Article Title: Graded heterogeneity of metabotropic signaling underlies a continuum of cell-intrinsic temporal responses

doi: 10.1101/2020.12.27.424473

Figure Lengend Snippet: a. Sample cell-attached recording (top) instantaneous firing rate (middle) and synaptic current measured with whole-cell voltage clamp (bottom) in a cell with fast response. b. Same as in A but for a cell with intermediate speed response c. Same as in A but for a cell with clear biphasic synaptic current (bottom) d. Same as in A but for a cell with slow biphasic response e. Same as in A but for a cell with only a pause in firing f. Half-decay times of firing rates vs. half-decay times of currents and linear fit on a log-log plot (R adj 2 = 0.91, slope = 0.88, intercept = -0.22, n = 17) g. Peak firing rate vs. peak current amplitude and linear fit on a log-log plot (R adj 2 = 0.69, slope = 0.71, intercept = -0.65, n = 17) h. Pause duration vs. amplitude of the current at stimulation offset, and linear fit with log 10 response variable (black, R adj 2 = 0.44, slope = 0.01, intercept = -0.42, n = 20) i. Heatmap of peak normalized mGluR1-mediated current (n=10) j. Heatmap of peak normalized mGluR2/3-mediated current (n=7) k. Average synaptic response before (black), after (red) mGluR1 antagonist, and after AMPA/NMDA receptor antagonist wash-ins (grey). Each trace is an average of 8 trials. l. Average synaptic response before (top, black) and after (top, blue) mGluR2/3 antagonist washin, and their difference (bottom, black). Each trace is an average of 8 trials.

Article Snippet: Sequential drug wash-ins were performed using a computer-controlled solenoid manifold system (ValveLink 8.2, Automate Scientific, Inc., Berkeley, CA) with a flow rate of 1 to 2mL/min, where indicated, with mGluR1 antagonist (100μM LY357385, Tocris Bio-Techne, Minneapolis, MN), AMPA receptor blocker (5μM NBQX), NMDA receptor blocker (2 μM R-CPP), mGluR2/3 antagonist (1μM LY341495, Tocris Bio-Techne, Minneapolis, MN) and DGK inhibitor II (100 μM R59949, MilliporeSigma, St. Louis, MO)

Techniques:

Journal:

Article Title: Excitability and Synaptic Communication within the Oligodendrocyte Lineage

doi: 10.1523/JNEUROSCI.6000-09.2010

Figure Lengend Snippet: (a) Plot of number of mEPSCs versus membrane capacitance. Cells were classified as NG2+ cells, Pre-OLs or OLs based on DsRed fluorescence, membrane capacitance, membrane resistance, and NaV current density. (b) Graph in a colored according to whether NaV current was detected, showing the tight correlation between loss of synapses and loss of NaV current. (c) HS-response of cells indicated by numbers in a and b. (d) Response of a representative NG2+ cell to glutamate uncaging (black dot), recorded at −80 mV and 40 mV (in NBQX/GYKI53655). (e) Response of a representative Pre-OL to glutamate uncaging at −80 mV and 40 mV (in NBQX/GYKI53655). (f) Response of representative OLs to glutamate uncaging recorded at −80 mV showing effects of NBQX/GYKI53655, RS-CPP (upper trace, 0 Mg++ACSF/3 μm D-serine), and TBOA (lower trace, normal ACSF); Insets show initial response at faster time scale (bar = 20 ms). (g) Quantification of peak AMPAR current normalized to membrane capacitance for NG2+ cells (n = 8), Pre-OLs (n=8), and OLs (n = 13); red asterisk: NG2+ cell vs. Pre-OL and NG2+ cell vs. OL, P < 0.001; blue asterisk: OL vs. Pre-OL, P < 0.001.

Article Snippet: The following agents were applied by addition to the superfusing ACSF: TTX (NaV antagonist; Ascent Scientific, 1 μM; gabazine (SR-95531; GABA receptor antagonist; Tocris, 5μM; RS-CPP (NMDA receptor antagonist; Tocris, 5μM or 20 μM for uncaging); 2,3-dihydroxy-6-nitro-7-sulfamoyl-benzo(f)quinoxaline (NBQX; competitive AMPA/kainate receptor antagonist; Tocris, 5 μM or 50 μM for uncaging); GYKI 53655 (AMPA selective, non-competitive antagonist; IVAX 100 μM; TBOA (competitive glutamate transporter blocker; Tocris, 300 μM).

Techniques: Membrane, Fluorescence